Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech giant Amgen
With that in mind, let's take a closer look at Amgen's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Thousand Oaks, Calif. (1980)|
|Market Cap||$54.0 billion|
|Trailing-12-Month Revenue||$15.6 billion|
|Management||Chairman/CEO Kevin Sharer (since 2000)
COO Robert Bradway (since 2010)
|Return on Equity (average, past 3 years)||19.4%|
|Cash/Debt||$20.6 billion / $21.4 billion|
Johnson & Johnson
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 92% of the 2,129 members who have rated Amgen believe the stock will outperform the S&P 500 going forward.
- Cash generator
- High margins
- Pays a dividend (just introduced it)
- Biotech might be the next big growth story (over the coming decade) although I'm not sure if Amgen will be an important part of this story
- Slow growth
- Huge debt
- Insiders sell everything they are allowed to sell at the moment they get it
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Amgen may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Novartis, as well as creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Will 2018 Be Amgen Inc.'s Best Year Yet?
It would take jumping some really high hurdles.
5 Things Amgen's CEO Just Said That Investors Need to Know
Bob Bradway focused on acquisitions, growth, and more at the J.P. Morgan Healthcare Conference.
2 Top Dividend Stocks to Buy in 2018
If you're looking for rock solid dividends, AbbVie and Amgen should be on your radar this year.